Heart failure & cardiomyopathiesSecondary analysis

Redefining response to cardiac resynchronization therapy: a post hoc analysis of the MORE-CRT MPP trial

EuropacePublished

  • Secondary analysis of the MORE-CRT MPP randomised trial
  • post hoc analysis

Authors' conclusion

Delayed responders demonstrated similarly favourable clinical outcomes to early responders over the duration of follow-up.

Study context

Population
Patients receiving conventional biventricular pacing only in the MORE-CRT MPP trial
Participants
2,732 patients
Comparison
Early vs delayed vs non-responders to cardiac resynchronization therapy (CRT)
Primary endpoint
HF hospitalization or death (event-free survival)

Primary result

As reported in the abstract

Non-responders vs Early responders
shorter event-free survival 52%; P < 0.001
Non-responders vs Delayed responders
shorter event-free survival 38%; P = 0.025

Further findings

HF hospitalization or death among 6-month non-responders, by 12-month trajectory · after 6 months · per_group values = share of non-responders

HF hospitalization or death among 6-month non-responders, by 12-month trajectory — Outcomes diverged after 6 months
P < 0.001
HF hospitalization or death among 6-month non-responders, by 12-month trajectory — Deterioration group: shorter event-free survival
59%
HF hospitalization or death among 6-month non-responders, by 12-month trajectory — Deterioration group: P
P < 0.001

Predictors of delayed response

Ischaemic aetiology, non-LBBB and lower baseline LVEF predicted delayed response

Original publication

Redefining response to cardiac resynchronization therapy: a post hoc analysis of the MORE-CRT MPP trial. Europace. Published 10 August 2026. doi:10.1093/europace/euag209

Summarised from the published abstract; every number is checked against it